Seres therapeutics reports first quarter 2023 financial results and provides business updates

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today reported first quarter 2023 financial results and provided business updates. “we were thrilled to recently announce the fda approval of vowst, the first and only fda-approved orally administered microbiota-based therapeutic, and with the favorable label indication received from the fda. adult recurrent c. difficile infection patients who could benefit from using vowst, pe.
MCRB Ratings Summary
MCRB Quant Ranking